SPOTLIGHT -
Dr. Morgans on the Current Treatment Landscape For mHSPC
Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.
Read More
Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer
Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.
Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer
Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.
Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials
Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.
Dr. Morgan on the Role of PARP Inhibitors in Prostate Cancer
Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.
Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer
Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)